Kymera Therapeutics (NASDAQ:KYMR) CFO Sells $8,864,450.64 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce Jacobs sold 77,109 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the sale, the chief financial officer owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kymera Therapeutics Stock Down 0.6%

Shares of KYMR traded down $0.69 during midday trading on Thursday, reaching $113.51. The company had a trading volume of 788,284 shares, compared to its average volume of 767,552. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $130.05. The firm has a 50 day simple moving average of $86.36 and a 200-day simple moving average of $82.74. The stock has a market cap of $9.34 billion, a PE ratio of -31.80 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter in the previous year, the company posted ($0.82) EPS. The company’s revenue was up 55.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of KYMR. Baker BROS. Advisors LP raised its stake in shares of Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC lifted its holdings in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares during the period. Finally, State Street Corp boosted its position in shares of Kymera Therapeutics by 9.4% during the 4th quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after purchasing an additional 190,383 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price target on the stock. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. B. Riley Financial increased their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Canaccord Genuity Group raised their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $121.41.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.